LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 358, Issue 4, 1998, Pages 500-502

  Konieczny, J ^a   Ossowska, K ^a   Wolfarth, S ^a   Pilc, A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Group II metabotropic receptors; Muscle rigidity; Parkinsonism

Indexed keywords

2 AMINOBICYCLO[3.1.0]HEXANE 2,6 DICARBOOXYLATE MONOHYDRATE; GLUTAMATE RECEPTOR AGONIST; HALOPERIDOL; METABOTROPIC RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG ACTIVITY; MUSCLE RIGIDITY; NEUROTRANSMISSION; PARKINSON DISEASE;

ANIMALS; ANTIPARKINSON AGENTS; BICYCLO COMPOUNDS; EXCITATORY AMINO ACID AGONISTS; HALOPERIDOL; MALE; MUSCLE RIGIDITY; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0031689603     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00005284     Document Type: Article

References (10)

1. Battaglia G, Monn JA, Schoepp DD (1997) In vitro inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY 354740 in rats. Neurosci Lett 229:161-164
2. Conn PJ, Pin J-P (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237
3. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallmann MJ (1997) LY 354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats. Neuropharmacology 36:1511-1516
4. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1998) Anxiolytic and side-effect profile of LY 354740: a potent, highly selective, orally active agonist lor group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660
5. Klockgether T, Turski L (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 12:285-286
6. Lorenc-Koci E, Wolfarth S, Ossowska K (1996) Haloperidol-increased muscle tone in rats as a model of parkinsonian rigidity. Exp Brain Res 109:268-276
7. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, Howe T, Alt CA, Rhodes GA, Robey RL, Griffey KR, Tizzano JP, Kallman MJ, Helton DR, Schoepp DD (1997) Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2.6-decarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40:528-537
8. Ossowska K (1994) The role of excitatory amino acids in experimental models of Parkinson's disease. J Neural Transm [Parkinson's Dis Dementia Sect] 8:39-71
9. Ossowska K, Lorenc-Koci E, Konieczny J, Wolfarth S (1998) The role of striatal glutamate receptors in models of Parkinson's disease. Amino Acids 14:11-15
10. Schoepp DD, Johnson BG, Wright RA, Salhoff CR, Mayne NG, Wu S, Cockerham SL, Burnett JP, Belegaje R, Bleakman D, Monn JA (1997) LY354740 is a potent and highly selective group II metabotropic receptor agonist in cells expressing human glutamate receptors. Neuropharmacology 36:1-11